MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2767-9764.crc-23-0460

Медицинская библиотека · Cancer research communications · 2025

A Proteomic Signature for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Predicts Patients at High Risk of Recurrence.

Jackson Christopher C, Liu Jia Jenny, Liu Howard Y, Williams Steven G, Anees Asim, Noor Zainab, Lucas Natasha, Xavier Dylan, Hains Peter G, Bucio-Noble Daniel, Aref Adel T, Porceddu Sandro V, Ladwa Rahul, Whitfield Joseph, Reddel Roger R, Zhong Qing, Panizza Benedict J, Robinson Phillip J

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

ABSTRACT: Although human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC) is associated with better prognosis than HPV-negative disease, ∼30% of cases relapse despite curative-intent radiotherapy (±chemotherapy). We aimed to develop a proteomic signature associated with risk of recurrence within HPV+OPSCC. We analyzed tumor specimens from 124 patients with T1–4N0–3M0 HPV+OPSCC: 50 patients with residual or recurrent disease within 5 years of treatment and 74 age and performance status–matched patients with no recurrence. Proteomic analysis was performed on archival formalin-fixed, paraffin-embedded primary tumor core biopsy specimens and matched normal adjacent tissues using quantitative data-independent acquisition mass spectrometry. Recurrence-free survival (RFS), both locoregional and distant, was the primary endpoint. Univariate Cox regression analysis identified peptides associated with RFS, from which a risk score was established to generate a peptide-based signature. A total of 7,597 protein groups were identified across the cohort, 1,565 of which were differentially abundant between tumor and normal adjacent tissues, with 1,218 being significantly increased in tumors. Improved 5-year RFS (q-value < 0.5) was associated with 405 differentially abundant peptides (from 233 unique proteins) within the 124 tumors. Among them a 26-peptide signature encompassing 26 protein groups was associated with RFS and was able to stratify patients into low, intermediate, or high risk of recurrence (concordance index = 0.941, P < 0.0001). Data available via ProteomeXchange PXD036891. Overall, a 26-peptide signature can be used to risk-stratify HPV+OPSCC. Validation of this proteomic prognostic signature in an independent cohort is required to assess its potential use in future clinical trials to better tailor initial therapy.

SIGNIFICANCE: HPV+OPSCC incidence is increasing, with heterogeneous treatment outcomes despite favorable prognosis. Current de-escalation strategies show inferior results, highlighting the need for precise risk stratification. Using data-independent acquisition mass spectrometry proteomics, we identified a 26-peptide signature that stratifies patients into risk categories, potentially enabling personalized treatment decisions and optimal patient selection for de-escalation trials.

Для цитирования: Jackson Christopher C, Liu Jia Jenny, Liu Howard Y, Williams Steven G, Anees Asim, Noor Zainab, Lucas Natasha, Xavier Dylan, Hains Peter G, Bucio-Noble Daniel, Aref Adel T, Porceddu Sandro V, Ladwa Rahul, Whitfield Joseph, Reddel Roger R, Zhong Qing, Panizza Benedict J, Robinson Phillip J. A Proteomic Signature for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Predicts Patients at High Risk of Recurrence.. Cancer research communications. 2025. DOI: 10.1158/2767-9764.crc-23-0460.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.